Author: admin

เทคโนโลยีสุขภาพระดับโลกเปิดตัวอย่างยิ่งใหญ่ เมื่อฉยงไห่ก้าวขึ้นเป็นผู้นำกระแสการดูแลสุขภาพ

ฉยงไห่, ประเทศจีน – Media OutReach Newswire – 28 มีนาคม 2569 – ระหว่างวันที่ 24–27 มีนาคมที่ผ่านมา การจัดแสดงเมืองภายใต้แนวคิด “Boao: Where the World Meets, Qionghai: Where Free Trade Thrives” (โป๋อ๋าว: จุดนัดพบของโลก | ฉยงไห่: เมืองแห่งการค้าเสรี) ได้จัดขึ้น ณ Dongyu Island Cultural Park เมืองโป๋อ๋าว โดยนับเป็นการจัดแสดงภาพลักษณ์เมืองครั้งสำคัญครั้งแรกนับตั้งแต่มณฑลไห่หนานเริ่มดำเนินศุลกากรแบบพิเศษทั่วทั้งเกาะไห่หนานภายใต้กรอบเขตการค้าเสรีไห่หนาน (Hainan Free Trade Port) โดยเปิดมุมมองแบบรอบด้านให้เห็นถึงบทบาทของฉยงไห่ในฐานะพื้นที่เชิงยุทธศาสตร์หลักของการค้าเสรีในมณฑลไห่หนาน การจัดแสดงครั้งนี้ร้อยเรียงเรื่องราวขึ้นภายใต้แนวคิดว่าด้วยการเชื่อมโยงโลกและการพัฒนาอย่างเปิดกว้าง โดยนำเสนอทั้งนโยบายและวัฒนธรรมผ่านประสบการณ์เสมือนจริงที่กระตุ้นทุกสัมผัส ด้วยการใช้การออกแบบและเทคโนโลยีล้ำสมัย

ไฮไลต์ภายในงานเริ่มต้นที่ “Digital Twin Experience Pod”ซึ่งเปิดโอกาสให้ผู้เข้าชมได้สัมผัสวิถีชีวิตของฉยงไห่ในอนาคต เพียงใช้บัตรประจำตัวประชาชนในการเข้าสู่ระบบ ขณะที่ศิลปะจัดวางแบบอินเทอร์แอ็กทีฟ “Cycle Through Qionghai” จะพาผู้เข้าชมออกเดินทางอย่างมีชีวิตชีวาเลียบแม่น้ำว่านฉวน (Wanquan River) ผ่านหมู่บ้านเก่าแก่สไตล์หนานหยาง (Nanyang) ซึ่งเป็นชุมชนที่ก่อตั้งขึ้นโดยชาวจีนโพ้นทะเลที่เดินทางกลับจากเอเชียตะวันออกเฉียงใต้ ก่อนจะพาเข้าสู่ทิวทัศน์ชายฝั่งและขุนเขาอันงดงามของฉยงไห่อย่างน่าประทับใจ

อีกหนึ่งไฮไลต์สำคัญคือการจัดแสดงเทคโนโลยีล้ำสมัยจากเขตนำร่องการท่องเที่ยวเชิงการแพทย์นานาชาติจีน โป๋อ๋าวเล่อเฉิง (Boao Lecheng International Medical Tourism Pilot Zone) โดยนวัตกรรมก้าวล้ำหลายรายการได้เปิดตัวต่อสาธารณชนพร้อมกันเป็นครั้งแรก ได้แก่เครื่องวัดระดับตาโปนอัตโนมัติเครื่องแรกของโลก, เครื่องตรวจวัดระดับน้ำตาลแบบไม่ต้องเจาะเลือด, ระบบจดจำใบหน้าสำหรับการคัดกรองทางพันธุกรรม และ อุปกรณ์สวมใส่ Ruiwatch ซึ่งล้วนสะท้อนให้เห็นอย่างชัดเจนว่า “นวัตกรรมการแพทย์ระดับโลกได้มาพบผู้ป่วยกลุ่มแรกในประเทศจีน”

ในฐานะเขตพิเศษด้านการท่องเที่ยวเชิงการแพทย์แห่งเดียวของจีน ฉยงไห่ไม่ได้เป็นเพียงศูนย์รวมของ “นวัตกรรมทางการแพทย์ล้ำสมัย” เท่านั้น หากยังเป็นจุดหมายปลายทางแห่งการดูแลสุขภาพด้วยธรรมชาติ เมืองแห่งนี้ผสานอุปกรณ์การแพทย์ระดับโลก นโยบายสิทธิประโยชน์ด้านการรักษา และระบบบริหารจัดการสุขภาพมาตรฐานสากลเข้าไว้ด้วยกัน จนทำให้ “การเข้าถึงบริการสุขภาพล้ำหน้าจากทั่วโลก”กลายเป็นเรื่องใกล้ตัวในชีวิตประจำวัน ตั้งแต่การแพทย์แม่นยำของเล่อเฉลิง ไปจนถึงการฟื้นฟูสุขภาพริมชายหาด และตั้งแต่การดูแลสุขภาพด้วยการแพทย์แผนจีน (TCM Wellness) ไปจนถึงการฟื้นฟูสมรรถภาพทางกีฬา ฉยงไห่กำลังก้าวสู่การสร้างระบบนิเวศแบบบูรณาการที่เชื่อมโยงการแพทย์ การดูแลสุขภาพ การท่องเที่ยว และการใช้ชีวิตเข้าไว้ด้วยกันอย่างสมบูรณ์

ภายหลังการเดินหน้าดำเนินงานของเขตการค้าเสรีอย่างเต็มรูปแบบ เมืองชายฝั่งแห่งนี้พร้อมเปิดรับผู้ที่รักสุขภาพจากทั่วทุกมุมโลกมาร่วมเริ่มต้นการเดินทางแห่งการฟื้นฟูร่างกายและจิตใจอย่างสมบูรณ์แบบ ที่ซึ่งนวัตกรรมการแพทย์อันล้ำสมัยมาบรรจบกับพลังแห่งธรรมชาติที่เปี่ยมล้นไปด้วยชีวิตชีวา ณ ฉงไห่ แห่งนี้

Hashtag: #CultureandTourismofGuizhouProvince #Qionghai

The issuer is solely responsible for the content of this announcement.

“Culinary Capital” Title Reaffirmed with Over 200 Restaurants Listed in Internationally Acclaimed Gourmet Guides

HONG KONG SAR – Media OutReach Newswire – 28 March 2026 – Following last year’s “The World’s 50 Best Bars” Award Ceremony in Hong Kong, the Hong Kong Tourism Board (HKTB) this year brought the “Asia’s 50 Best Restaurants 2026” Awards Ceremony to Hong Kong for the first time. The event today (25 March) brought together over 1,000 culinary industry representatives, renowned chefs and media worldwide. Top local Cantonese restaurant The Chairman and contemporary Cantonese restaurant Wing secured first and second places respectively on the Asia’s 50 Best Restaurants 2026 list, once again highlighting the leading position of Hong Kong’s dining scene in Asia.

HKTB Chairman Dr Peter Lam said: “We extend our sincere gratitude to the Asia’s 50 Best Restaurants team for selecting Hong Kong for the first time as the host city for the Awards Ceremony. This international award recognises the outstanding achievements of the culinary sector. I am very proud of Hong Kong’s remarkable accomplishments in this year’s Awards. Together with the ‘MICHELIN Guide Hong Kong Macau 2026’ and ‘The Black Pearl Restaurant Guide’, over 200 restaurants have been listed in these internationally acclaimed gourmet guides, reaffirming Hong Kong’s position as a “Culinary Capital” in Asia. We are delighted to welcome the esteemed Asian chefs and other culinary professionals attending the Awards Ceremony to Hong Kong, and we warmly invite everyone to explore the city’s unique and diverse gastronomic charm by following the master chefs’ curated recommendations featured in the citywide ‘Taste Hong Kong’ Gourmet Guide.”

Danny Yip, owner of The Chairman, said “Being named The Best Restaurant in Asia for the second time is a huge honour for our entire team, and to achieve it here in Hong Kong makes it even more meaningful. This recognition — as well as the strong results for the city on this year’s list — reflects the depth and diversity that define Hong Kong’s dining culture today. It’s a privilege to represent our city in this way and to continue sharing the traditions and stories that shape our cuisine.”

Hong Kong Leads Asia Culinary Landscape with Two Restaurants in the Top Three

Together with the previously announced extended list of Asia’s 50 Best Restaurants (51^th – 100^th), a total of ten Hong Kong restaurants were recommended in the Asian edition of the prestigious list. These include six restaurants in the top 50: while The Chairman and Wing topped the list at first and second spots, Neighborhood (No. 24), Estro (No. 32), Caprice (No. 35), and Mono (No.46) stayed strong on the list. Four other restaurants were also feature in the extended list, namely Ta Vie (No. 68), Vea (No. 70), Andō (No. 88), and Amber (No. 90). With this stellar performance, Hong Kong reaffirming its leading position in the regional culinary scene. The winning restaurants cover a diverse range of cuisines, demonstrating Hong Kong’s unique appeal as a melting pot of global flavours and a hub for star-rated dining establishments.

In the recently announced “Black Pearl Restaurant Guide”, the number of Hong Kong entries increased to 39, up from last year, including four first-time entries – Mosu Hong Kong, founded by three-Michelin-star South Korean chef Sung Anh; Jee, a Cantonese-French fusion restaurant; contemporary Indian restaurant Leela, and Cantonese fine-dining establishment Man Ho Chinese Restaurant. In addition, homegrown chef Vicky Cheng of Chinese-French restaurant VEA, and Terry Ho, Chef de Cuisine of French restaurant Amber, received the Master Chef Award and the Young Chef Award respectively in the Black Pearl Restaurant Guide, affirming the distinguished reputation of Hong Kong’s culinary talent in the Asian dining scene. In the “MICHELIN Guide Hong Kong Macau 2026”, more Hong Kong establishments were awarded MICHELIN stars than in the previous year, bringing a total to 77 Michelin-starred restaurants in one destination, further demonstrating the world-class standard of the city’s culinary scene.

Top Asian Chefs and Global Media Gather in Hong Kong to Experience the City’s Culinary

Capitalising on the opportunity presented by major culinary event being hosted in Hong Kong, HKTB arranged exchanges between leading Asian chefs and renowned local culinary talent, enabling them to experience the city’s diverse gastronomic offerings and produce promotional videos dedicated to “Taste Hong Kong”. In addition, HKTB leveraged its global network to invite media representatives from the Chinese Mainland, Taiwan, South Korea, Southeast Asia and other key markets to visit Hong Kong. In addition to attending the award ceremony for media coverage of the event, HKTB curated a series of immersive culinary experiences to fully showcase Hong Kong’s unique charm as a Culinary Capital.

Highlights of the itinerary included engaging with local master chef Vicky Cheng to gain firsthand insight into his exceptional culinary skills and cooking philosophy; participating in a dim sum workshop led by master chef Wong Lung-to, Executive Chef of Forum Restaurant, to learn how to make classic Cantonese dim sum such as siu mai (Cantonese pork dumplings) and har gow (shrimp dumplings); and joining an egg tart baking workshop. Media representatives were also invited to dine at several listed restaurants and visit emerging bars to experience Hong Kong’s diverse food and beverage culture in full. Through in-depth media coverage, the media trip will help promote Hong Kong’s distinctive culinary appeal to audiences worldwide, attracting more visitors to explore “Taste Hong Kong” and further consolidating the city’s status as a Culinary Capital.

11 Exclusive Collaborative Signature Sessions around the Awards Ceremony to Share Hong Kong’s Gastronomic Experiences

To encourage locals and visitors to immerse themselves in the vibrant atmosphere surrounding the award ceremony, HKTB partnered with the organiser for the first time this year to invite 40 internationally renowned and local award-winning restaurants to present 11 limitedtime collaborative Signature Sessions covering various global cuisines, bringing multiple tasting surprises to locals and visitors. The events attracted many locals and visitors, allowing everyone to experience the charm of global cuisines converging in Hong Kong at a single table.

Popular Variety Shows Drive Tourism and Encourage Visitors to Experience Hong Kong’s Diverse Culinary Delights through “Taste Hong Kong”

In line with the “Taste Hong Kong” Gourmet Guide launched in January, which covers all neighbourhoods across the city and features chef-recommended restaurants, HKTB has stepped up its promotional efforts in key source markets, such as the Chinese Mainland, Taiwan, New Zealand, South Korea and Southeast Asia. By collaborating with popular local food variety shows, HKTB showcased Hong Kong’s diverse dining culture to wider audiences, further enhancing international interest in Hong Kong’s culinary tourism.

In the Chinese Mainland, HKTB promoted culinary travel to Hong Kong through a Chinese New Year food programme on Shenzhen Satellite TV, with master chefs introducing restaurants recommended in the Guide and visiting specialty streets such as “Dried Seafood Street” and Shanghai Street, locally known as “Kitchenware Street”, to explore the charm of Hong Kong’s neighbourhoods. HKTB also partnered with New Zealand’s popular programme Seven Sharp, inviting media to visit Sham Shui Po to taste authentic local snacks, such as pineapple buns, milk tea, tofu pudding and dumplings, and to dine at a time-honoured Western restaurant to sample Swiss chicken wings and soufflé, showcasing Hong Kong’s diverse food culture. In addition, HKTB collaborated with Taiwan’s Super Taste, South Korea’s Boss in the Mirror, and multiple travel and food programmes in Thailand and the Philippines, featuring visits to recommended restaurants and exchanges with local master chefs. Through the broad influence of these variety shows, HKTB is actively showcasing the unique charm of “Taste Hong Kong”, attracting more visitors to embark on a culinary journey in Hong Kong.

Full results of Asia’s 50 Best Restaurants 2026: https://www.theworlds50best.com/asia/en/list/1–50
Hashtag: #HKTB

The issuer is solely responsible for the content of this announcement.

With emotional depth, singer Natalia Sarsgard describes the path to finding oneself again, to gathering one’s thoughts, to remaining silent, to withdrawing—in order to reflect in the silence, in the comfort, and in the seclusion, to feel and reconnect with ourselves and others.

Through her multifaceted voice, Natalia Sarsgard’s interpretation of the song conveys how strength and courage can arise from deep vulnerability. Without even realizing it, one is accompanied by the confidence that what was thought to be lost can be found again.

Youtube: https://youtu.be/CINjhTHtmno

J’ai Du M’arreter – LPS, https://open.spotify.com/intl-de/album/6BvbJ0VAAvMwciCD7q7BC8
https://shop.valle-venia.de/products/different-ways
https://www.amazon.de/Different-Ways-feat-Various-Artist/dp/B0CMJVQV2M
https://valle-venia.de/30S/JaiDuMarreter.mp4

www.valle-venia.com
Hashtag: #ValleVenia

The issuer is solely responsible for the content of this announcement.

Cheryl Ang, Head of Marketing at Shopee Malaysia, shared, “Shoppers today are looking beyond one-off discounts for more consistent benefits in how they shop day to day. We’re seeing this with Shopee VIP members, who shop more frequently and rely on perks like Daily Free Shipping No Minimum Spend, early access to deals, and vouchers. With the Shopee 4.4 Super VIP Sale, we’re enhancing these core benefits, while introducing additional partner deals that support how our users live, work, and unwind.”

More Free Shipping No Minimum Spend on Everyday Orders

Saving on delivery is just as important as saving on the product itself. This Shopee 4.4 Super VIP Sale, Shopee VIP members will enjoy unlimited Daily Free Shipping No Minimum Spend vouchers, allowing them to check out anytime, whether it’s a single item or smaller purchases, without needing to bundle orders or worry about delivery costs. These vouchers can also be stacked with platform vouchers for greater savings.

Early Access to Top Deals with Vouchers Worth Over RM4,400

For many shoppers, the biggest challenge isn’t finding deals, but getting in early enough to secure them. With Shopee VIP, members get priority access to Shopee 4.4 Super VIP Sale deals from 3 April, 12AM onwards, giving them a clear advantage when it comes to limited offers.

Highlights include:

• VIP Exclusive 50% Off Lagi Murah Deals from Montigo, Laneige, and Huawei
• RM14 Knockout Deals from Gintell, TCL, and Poh Kong, available to Shopee VIP members from 3 April, 12AM, ahead of the public release at 8PM

Beyond early access deals, Shopee VIP members can enjoy ongoing savings throughout the campaign with VIP vouchers worth over RM4,400, including hourly 30% off vouchers and extra 15% off seller vouchers on 3 and 4 April.

Lifestyle and Productivity Perks That Go Beyond Shopping

Travel and entertainment benefits remain popular among Shopee VIP members, alongside growing demand for productivity tools that support everyday tasks.

From planning a getaway to streaming favourite shows, staying active, or even getting help with everyday tasks, Shopee VIP members can unlock perks that fit into how they live and work. Members can access exclusive deals with partners such as Trip.com, iQIYI, VIU, ClassPass, and ChatGPT:

• Travel: Up to 9% off hotel stays and 4% off flights on Trip.com, with no minimum spend
• Entertainment: Free 14-day iQIYI VIP trial, 30% off iQIYI 1-Year VIP, and a free 3-month VIU subscription
• Fitness: Free 1-month ClassPass trial for new users plus 5 bonus credits, and 15 bonus credits for existing users with any plan upgrade
• Productivity: Free 3-month access to ChatGPT Go (worth RM116)

A More Rewarding Way to Shop with Shopee VIP

This Shopee 4.4 Super VIP Sale brings together Daily Free Shipping with No Minimum Spend, early access deals of up to 50% off, and VIP vouchers worth over RM4,400, giving members more ways to benefit across every purchase.

Start with Shopee VIP’s free 1-month trial, then continue at just RM4.50 per month. Find out more at: https://shopee.com.my/m/Shopee-VIP
Hashtag: #Shopee

The issuer is solely responsible for the content of this announcement.

About Shopee

Shopee is a leading e-commerce platform in Southeast Asia, Taiwan, and Brazil. Shopee promotes an inclusive and sustainable digital ecosystem by enabling businesses to digitalise and grow their online presence, helping more people access and benefit from digital services, and uplifting local communities.

Shopee offers an easy, secure, and engaging experience that is enjoyed by millions of people daily. Shopee is also a key contributor to the digital economy, with a firm commitment to helping homegrown brands and entrepreneurs succeed in e-commerce.

Shopee is part of Sea Limited (NYSE: SE), a global technology company. Sea’s mission is to better the lives of consumers and small businesses with technology through its three core businesses: Shopee, Garena, and Monee.

Final Dividend Increases by 33.3% to HK10 Cents per Share

Dual Engines, Global Reach: B2C-B2B Synergy Drives Market Expansion

Results Highlights

• Revenue hit a new high of US$501.54 million, representing a strong YoY growth of 45.0%
• Gross profit rose by 40.9% to US$148.50 million; operating profit increased by 28.2% to US$31.90 million
• Net profit grew by 21.5% to US$23.14 million
• The Board has proposed a final dividend of HK10 cents per share, up 33.3% year-on-year
• Business-to-consumer (B2C) platform YesStyle recorded revenue of US$347.48 million, up 30.8%, accounting for 69.3% of the Group’s total revenue
• Revenue of business-to-business (B2B) platform AsianBeautyWholesale (ABW) surged by 91.7% to US$148.89 million, accounting for 29.7% of the Group’s total revenue
• Non-core markets (excluding the US, UK, Canada, Australia) accounted for over 60% of the Group’s total revenue for the first time, with Latin America and the Middle East achieving remarkable growth
• The Group strengthened its global logistics network to improve economies of scale, opened a second AMR warehouse in Hong Kong and a new warehouse in South Korea, reducing freight costs as a percentage of revenue to 18.7%

HONG KONG SAR – Media OutReach Newswire – 27 March 2026 – YesAsia Holdings Limited (“YesAsia Holdings”, together with its subsidiaries, the “Group”) (02209.HK), a leading e-commerce platform operator recognized for its expertise in curating Asian beauty and lifestyle products, announced today its annual results for the year ended 31 December 2025 (the “Year”).

The Group’s revenue rose by 45.0% to US$501.54 million, boosted by the global K-Beauty momentum and the scaled expansion of its B2B platform, which accounted for nearly 30% of the Group’s revenue. Gross profit increased by 40.9% to US$148.50 million, and gross profit margin remained relatively stable at 29.6%. Operating profit also grew by 28.2% to US$31.90 million. Net profit for the Year climbed 21.5% to US$23.14 million, with a net profit margin of 4.6%. Basic earnings per share was US5.62 cents (2024: US4.74 cents).

As at 31 December 2025, the Group maintained a solid financial position with bank and cash balances amounting to US$15.94 million. In the view of YesAsia Holdings’ solid operating performance, healthy cash reserves and future capital requirements, the Board has proposed a final cash dividend of HK10 cents per share (2024: HK7.5 cents per share).

Market diversification pays off as non-core markets lead global growth

Building on stable revenue from its core markets (the US, UK, Canada, and Australia), the Group accelerated its expansion into mainland Europe, Latin America, the Middle East, and other emerging markets. In 2025, non-core markets accounted for over half of the Group’s total revenue, significantly outpacing core markets in growth and becoming the primary catalyst of its business across the globe. Among these regions, Latin America and the Middle East recorded the strongest upward trend, with growth of 224.4% and 75.5% respectively, while Europe and Associated Countries remained the Group’s largest regional market.

Social media marketing and influencer engagement remain core drivers of YesStyle‘s growth strategy. During 2025, the number of YesStyle influencers increased to over 502,000, representing a year-on-year growth rate of approximately 24.6%. Revenue generated from influencer referrals reached approximately US$104.8 million, up approximately 43.0% year‑on‑year, and accounted for approximately 30% of YesStyle‘s total revenue, highlighting the continued strengthening of the YesStyle influencer ecosystem.

Meanwhile,YesStyle bolstered its localization efforts to capture opportunities in non-English-speaking markets. In July 2025, it launched a Polish-language website, expanding its language offerings to nine. Combined with social-media-driven marketing, regional campaigns via a robust network of influencers, and AI-powered solutions, the Group extended K-Beauty’s reach to a broader audience worldwide. This momentum is further amplified by the opening of Yesful Land in Seoul, South Korea, a physical hub where influencers and the K-Beauty community can converge and create authentic content, bridging digital engagement with real-world experience.

B2C-B2B synergy fuels performance with ABW business scaling rapidly

YesAsia Holdings is an authorized distributor for over 475 K-Beauty brands, serving both B2C and B2B channels. The dual-growth-engine strategy continued to bear fruit in 2025, fortifying the Group’s overall market influence and ongoing advancement.

Notably, ABW maintained its vigorous growth trajectory in 2025, with the newly launched ABW Offline business generating almost US$50 million in revenue in its debut year, underscoring the strong international retail demand for K-Beauty products. During the Year, ABW established distribution networks for 56 leading retailers across 26 markets, spanning North America, Europe, Latin America, the Middle East and Asia. Prominent partners include Target, Costco, Primark, Douglas, Sally Beauty, Watsons, and Nykaa. These collaborations have enabled the Group and its K-Beauty brand partners to reach millions of consumers through established offline retail networks, effectively tapping into a market segment that remains significantly larger than its online counterpart.

Mr. Joshua Lau, Founder, Executive Director and Chief Executive Officer, said: “Looking ahead, we are confident that K-Beauty’s global development impetus will only gather steam as it has transitioned from a niche category into a mainstream retail staple. To capture the opportunities that arise, we will deepen engagement in non-core markets through targeted and localized digital initiatives. At the same time, we are accelerating our B2B business by connecting K-Beauty brands with international retailers, and leveraging our logistics network and AI-driven capabilities. With dual growth engines in B2C and B2B, advanced technology, and a dedicated team, YesAsia Holdings is well-positioned to soar to new heights and deliver long-term value to shareholders and stakeholders.”

Hashtag: #YesAsiaHoldings

The issuer is solely responsible for the content of this announcement.

About YesAsia Holdings Limited (02209.HK)

Established in 1997, YesAsia Holdings is a leading e-commerce platform operator recognized for its expertise in identifying and procuring quality Asian beauty, fashion, lifestyle and entertainment products. Headquartered in Hong Kong, the Group deliver products promptly and efficiently to a global audience through its strong ties with over 400 leading Asian beauty brand and supplier partners. The Group operates three major platforms: YesStyle, an e-commerce B2C platform for serving the increasingly popular Asian beauty, fashion and lifestyle products, particularly Korean beauty products; AsianBeautyWholesale, a B2B platform for Asian beauty products; and YesAsia, an e-commerce retail platform for entertainment products. YesAsia Holdings is a constituent of the MSCI Hong Kong Micro Cap Index.

For more information, please visit the Group’s official website: https://www.yesasiaholdings.com/

多重奖赏: 2X 奖赏积分及Mastercard 签账赏高达 HK$1,000 回赠

香港 – Media OutReach Newswire – 2026年3月27日 – HKairport Rewards 呈献复活节缤纷购物礼遇，包括 2 倍积分、高达 HK$1,000 Mastercard 机场现金券及尊尚腕表HK$6,000购物赏优惠，为旅客的复活节旅程增添惊喜与欢乐。

复活节购物赏登场 立即解锁机场彩蛋优惠
临近复活节假期，HKairport Rewards 为会员呈献多重限定购物礼遇，让旅客于出发前在机场轻松选购各式精品及香港特色手信：

1. 享2X 积分，回赠高达 8%
由 3 月 27 日起至 4 月 12 日期间，旅客于机场店铺或 HKairportShop.com 机场网上商店消费，均可享 2 倍奖赏积分，回赠高达 8%。

每消费港币 $1 可获 2 奖赏积分；每 50 积分即可兑换 1 HKIA Dollar，可当作港币 $1 使用。 HKIA Dollar 可于机场超过 100 间参与商户及餐厅使用，让旅客尽享购物及餐饮礼遇。

2. Mastercard签账奖赏高达港币$1, 000回赠
于 3 月 20 日至 4 月 12 日推广期内，旅客于机场店铺或HKairportShop.com机场网上商店以 Mastercard单一消费满指定金额，即可获赠 Mastercard 机场电子现金消费券，解锁多重购物奖赏。

每名会员于推广期内可兑换各消费级别之Mastercard机场电子现金券一次。

3. 尊尚腕表$6,000购物优惠
另外，HKairport Rewards 会员由3月12日至 4 月 12 日期间，于机场选购腕表或相关配件，单一消费满港币 50,000 元，即可享立减港币 6,000 元，相当于12% 折扣，同时可享2X 积分及Mastercard签账奖赏!会员只需于「My HKG」流动应用程式内输入奖赏代码「WATCH」，即可领取港币 6,000 元电子现金券。参与推广的 9 间国际知名品牌包括：Bulgari、Cartier、Chaumet、IWC SCHAFFHAUSEN、Jaeger-LeCoultre、Montblanc、Panerai、Piaget及Tiffany & Co.。

每名会员于推广期内仅限兑换港币 6,000 元电子现金券一次。

按此了解更多优惠详情。

香港国际机场网上商店春季漫游赏 优惠低至5折

春日翩然而至，HKairportShop.com 机场网上商店提供：从清新色彩的行李箱，气味迷人的春日香水、或在初春出游期间享用的美酒佳酿，部分产品低至５折优惠，准备好让您的每段旅程都称心满意。由即日起至2026年3月31日， 凡于HKairportShop.com 单一消费净额满港币3,000元，即可获赠新秀丽旅行卡槽斜背袋乙个（价值港币380元），让随身物品轻松收纳！

按此了解更多香港国际机场网上商店最新优惠。

Hashtag: #香港国际机场

The issuer is solely responsible for the content of this announcement.

香港 – EQS Newswire – 2026年3月27日 – 综合性生物制药公司 — 联康生物科技集团有限公司（「联康集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：0690）欣然宣布本集团截至二零二五年十二月三十一止年度(「年内」）的全年业绩。

二零二五年取得之重大成就
年内，本集团取得了一系列成就，在已上市产品及创新的生物制剂方面均取得良好成绩。主要取得的成就如下:

1. 年内，本集团录得破纪录的财务业绩，收入按年增长6. 0%，达到约586. 2百万港元。溢利按年升12.7%至约93.3百万港元，而纯利率按年增加1. 0个百分点至15.9%，创历史新高。每股盈利达到约1. 56港仙，按年增长15.5%，二零二三年至二零二五年的复合年增长率为18.55%。
2. 本集团于年内录得稳健的经营现金流，经营现金流量及自由现金流量分别按年增加32.7%及27.3%。现金比率由二零二四年底的0.53倍上升至二零二五年底的1.63倍。现金转换周期从124天改善为107天，突显营运效率显著提升。凭借可持续盈利及稳健的现金流，董事会建议派发末期股息每股0.313港仙。
3. 自博固泰®于二零二四年三月正式推出以来，在稳健的商业化策略及成功的学术推广驱动下，其保持了强劲的增长势头。于二零二五年，博固泰^®在中国展现出快速的市场渗透率，年收入增长实现111.0%的显著增长。
4. 于二零二五年五月，本集团第二款眼部产品金因康^®（地夸磷索钠滴眼液）获中国国家药品监督管理局(NMPA)的上市批准，标志着继金因舒^®后，本集团眼部产品线拓展之重要里程碑。本集团正积极筹备其推出及营销策略。除利用与金因舒^®及其成熟的在线及线下分销网络的协同效应以实现快速市场渗透外，金因康^®将专门针对医院场景以外的中高端干眼症患者群体，即该等优先考虑长期疗效及优质产品质量的患者。
5. 于二零二五年六月，本集团正式推出肌颜态^®高端系列GeneQueens^®及医疗器械品牌金因敷^®，此举标志其进军「药品、医械及医美」整合领域之两个关键里程碑。该等产品发布反映本集团致力于完善其皮肤健康产品矩阵，并满足消费者对功能性护肤及医美术后修复领域中以功效为导向的医学级护肤品不断演变的需求。
6. 于二零二五年七月，硫酸艾沙康唑胶囊的上市申请已获国家药品监督管理局正式受理。硫酸艾沙康唑胶囊预计最早将于二零二六年第四季度获准上市，为侵入性真菌感染患者提供更安全、更有效且高质量的治疗选择。
7. 于二零二五年，本集团与温州医科大学建立战略合作伙伴关系，利用该大学在bFGF生产方面经证实的专业知识，共同研发结合EGF及bFGF的热敏凝胶制剂。作为再生医学的关键生长因子，bFGF在促进肉芽组织增生及血管生成方面具有高度疗效。
8. 于二零二五年底，本集团将其长期战略由「稳健增长」重新定位为「创新驱动」，标志着其由一家综合制药公司大胆转型为全球再生医学先驱。本集团正推进具变革性的研发战略方向，涵盖四大关键领域：肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉科再生。

全年业绩

于二零二五年，本集团录得收益约586. 2百万港元，按年增长6. 0%。博固泰^®的收益由约63.5百万港元大幅增加至约134.0百万港元，大幅增加111.0%。金因肽^®的收益约为220.4百万港元，按年增长10.9%。由于市场竞争激烈，金因舒^®的收益由约41.9百万港元按年减少7.9%至约38.6百万港元。匹纳普^®录得的收益由约244.2百万港元减少29.4%至约172.5百万港元。二零二五年，本集团在带量采购下采取了更为严谨且具选择性的医院供应策略，以保障利润率，特别是在政策调整加剧价格竞争的地区。同时，本集团加速向传统医院渠道以外的药房网络多元化发展，并优化其供应链以改善成本及盈利能力。于二零二四年，博舒泰^®成功纳入河南省十七省联盟集中带量采购，采购有效期设定为两年。于二零二五年，许多省份的医院开始采购博舒泰^®。继二零二四年的去库存及较低基数之后，来自博舒泰^®的收益由约10.2百万港元增加至约15.5百万港元，大幅增加51.9%。肌颜态^®在其早期阶段产生约2.8百万港元的收益。有限的收益规模反映了几项因素，包括于年内获批准及推出的产品数量相对较少，以及专业营销及分销团队仍处于组建及优化阶段的事实。

毛利约为487.6百万港元，较二零二四年的约461.1百万港元增加5.7%，而毛利率按年下降0.2个百分点至83.2%。本集团实现约93.3百万港元的破纪录溢利，再次创下新高，按年增长12.7%。净利润率按年上升1.0个百分点至15.9%。该等业绩证明本集团凭借强大的商业化执行力及财务纪律，成功将产品创新转化为市场价值。每股盈利约达1.56港仙，按年增长15.5%。

展望

再生医学已成为一个快速发展的领域，专注于利用细胞、组织或遗传物质修复、更换或再生受损的组织或器官。该行业具有治疗及解决慢性病及晚期疾病潜在病因的潜力。全球再生医学市场于二零二五年约为517亿美元。预计将由二零二六年的630亿美元增长至二零三四年的5,556亿美元，复合年增长率为31.3%。慢性病及遗传性疾病日益普遍，加上发达及新兴市场的医疗保健支出不断增加，预计将支持再生医学行业持续增长。

联康生物科技集团主席梁国龙先生表示：「二零二五年，我们欣然宣布公司又实现了一年的营利突破，标志着集团发展中重要的里程碑。年内，本集团进入策略发展的新阶段。随着市场环境逐步向好，我们积极推进由『稳定增长』转型至『创新驱动』阶段，聚焦肌肉骨骼再生、皮肤再生、眼部再生及耳鼻喉再生四大多元化治疗领域。

随着多项产品正在研发并加速迈向商业化阶段，集团持续拓展多元化营销渠道。在巩固传统医疗网络、加深与本地经销商合作以及开展学术推广活动的同时，我们亦积极布局在线电商平台，以进一步提升产品可及性以及扩大市场覆盖。我们的发展战略不限于中国市场。年内，我们与科兴制药建立了战略合作关系，共同推动博固泰^®的全球化布局。通过此次合作，我们已授权博固泰^®在沙特阿拉伯、埃及、摩洛哥、哥伦比亚、阿根廷及墨西哥六个国际市场的独家商业化权利，为全球业务拓展奠定坚实基础。我们预计上述市场最早将于2026年底开始贡献收益。与此同时，我们正积极推进博固泰^®在美国的FDA注册审批。

二零二五年十二月，我们与温州医科大学及温州市瓯海区人民政府达成战略合作，致力于构建『政产学研』的协同模式，进一步提升公司在再生医学领域的能力。凭借地方政府与顶尖学术机构的有力支持，我们有信心打造一流的生物医药生态体系，以提升全周期能力。」
Hashtag: #Uni-BioScience #联康生物科技

The issuer is solely responsible for the content of this announcement.

关于联康生物科技集团有限公司

联康生物科技集团有限公司是一家于2001年在香港联合交易所主板上市的创新型生物医药企业（股票代码：00690.HK），致力于以下一代合成生物学技术与复杂多肽创新，驱动再生医疗发展。本集团聚焦于骨骼/肌肉再生、皮肤再生、眼部再生及耳鼻喉（ENT）再生四大核心研究领域，构建了涵盖生物创新药、高值仿制药与医疗美容等板块的多元化产品管线。本集团分别于北京、东莞及深圳均设有GMP的生产基地，具备研发、生产及商业化销售的全链条能力。本集团致力于成为再生医学领域的全球领导者，重新定义科学如何修复与延展人类生命。

如欲了解更多信息，请联系： ir@uni-bioscience.com

HONG KONG SAR – EQS Newswire – 27 March 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).

Key Accomplishments in 2025
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. During the Year, the Group delivered record-breaking financial results, with revenue recorded a 6.0% year-on-year (“YoY”) increase, reaching approximately HK$586.2 million. Profit for the year soared by 12.7% YoY to approximately HK$93.3 million, and net profit margin increased by 1.0 percentage points YoY to 15.9%, marking a historic high. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
2. The Group generated solid cash from operations in the Year, operating cash flow and free cash flow increased by 32.7% and 27.3% YoY, respectively. Cash ratio increased from 0.53 times at the end of 2024 to 1.63 times at the end of 2025. The cash conversion cycle improved from 124 days to 107 days, highlighting greater operating efficiency. Backed by sustainable earnings and a healthy cash flow, the board of directors (“Board”) has declared a dividend payment for 2025 of HK$0.313 cents per share.
3. Since its official launch in March 2024, Bogutai^® has sustained strong growth momentum, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai^® demonstrated rapid market adoption in China, achieving a remarkable year-on-year revenue growth of 111.0%.
4. In May 2025, the Group’s second ophthalmology product, 金因康^® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration (“NMPA”), marking a significant milestone in expanding the Group’s ophthalmic portfolio following GeneSoft^®. The Group is actively preparing its launch and marketing strategy. In addition to leveraging synergy with GeneSoft^® and its established online and offline distribution network for rapid market penetration, 金因康^® will specifically target the mid-to-high-end segment of dry eye patients outside the hospital setting, those who prioritize long-term efficacy and premium product quality.
5. In June 2025, the Group officially launched the high-end series GeneQueens^® of 肌顏態^® and the medical device brand 金因敷^®, marking two key milestones in its strategic expansion into the integrated”Drug, Medical Device, and Aesthetics”field. These product launches reflect the Group’s commitment to enhancing its skin health product matrix and addressing evolving consumer needs for efficacy-driven, medical-grade skincare in both functional skincare and post-aesthetic recovery.
6. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. Isavuconazonium sulfate capsules are expected to be approved for launch as early as the fourth quarter of 2026, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections.
7. In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore a thermosensitive gel formulation combining EGF and bFGF, leveraging the university’s proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis.
8. Towards the end of 2025, the Group repositioned its long-term strategy from “Stable Growth” to “Innovation-Driven,” signifying a bold transformation from an integrated pharmaceutical company into a global pioneer in regenerative medicine. The Group is advancing a transformative R&D strategy spanning four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

Annual Results
For 2025, the Group recorded a revenue of approximately HK$586.2 million, representing an increase of 6.0% YoY. Revenue from Bogutai^® increased from approximately HK$ $63.5 million to approximately HK$ 134.0 million, representing a significant increase of 111.0%. Revenue generated from GeneTime^® was approximately HK$220.4 million, representing an increase of 10.9% YoY. GeneSoft^® recorded a 7.9% YoY decrease in revenue from approximately HK$41.9 million to approximately HK$38.6 million due to intense market competition. Pinup^® recorded a decrease of 29.4% in revenue from approximately HK$244.2 million to approximately HK$172.5 million for the Year. In 2025, the Group adopted a more disciplined and selective hospital-supply strategy under volume-based procurement (VBP) to safeguard margins, particularly in regions where policy adjustments intensified price competition. At the same time, the Group accelerated diversification into pharmacy networks beyond traditional hospital channels and optimized its supply chain to improve cost and profitability. In 2024, Boshutai^® was successfully included in the VBP by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years. Hospitals in many provinces began procuring Boshutai^® in 2025. Following the destocking and a low base in 2024, revenue from Boshutai^® increased from approximately HK$10.2 million to approximately HK$15.5 million, representing a significant increase of 51.9%. 肌顏態^® generated approximately HK$2.8 million in revenue in its early stage. The limited revenue scale reflected several factors, including a relatively small number of products approved and launched during the Year, and the fact that specialized marketing and distribution teams were still being built and optimized.

Gross profit was approximately HK$487.6 million, representing an increase of 5.7% as compared with approximately HK$461.1 million in 2024, and gross profit margin increased by 0.2 percentage points YoY to 83.2%. The Group delivered another year of record-breaking profit, achieving approximately HK$93.3 million for the Year, representing an increase of 12.7% YoY. Net profit margin increased by 1.0 percentage points YoY to 15.9%. These results demonstrate the Group’s success in converting product innovation into market value through strong commercialization execution and financial discipline. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY.

Prospects
Regenerative medicine has emerged as a rapidly developing field, focused on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. The sector has the potential to treat and address the underlying causes of chronic and advanced diseases. The global regenerative medicine market was approximately USD51.7 billion in 2025. It is projected to grow from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual growth rate (CAGR) of 31.3%. The increasing prevalence of chronic and hereditary diseases, together with rising healthcare expenditure in both developed and emerging markets, is expected to support continued growth in the regenerative medicine industry.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “In 2025, we are proud to have delivered another year of record profitability, marking a significant milestone in our growth journey. During the year, we entered a new phase of strategic development. In anticipation of an increasingly favorable market environment, we advanced our strategic transition from ‘stable growth’ to ‘innovation-driven’ development, with a clear focus on four diversified therapeutic areas: musculoskeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

With multiple products progressing through our pipeline and accelerating toward commercialization, the Group has continued to broaden its marketing channels. In addition to strengthening our established offline hospital networks, deepening partnerships with local distributors, and hosting academic conferences, we have actively expanded into online e-commerce platforms to enhance product accessibility and extend our market reach. Our ambitions extend well beyond China. During the year, we formed a strategic partnership with Kexing Biopharm to accelerate the global expansion of Bogutai^®. Through this collaboration, we have granted Kexing Biopharm exclusive commercialization rights for Bogutai^® in six international markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico—laying a solid foundation for global growth. We expect these markets to begin contributing revenue as early as the end of 2026. At the same time, we are advancing the FDA approval process for Bogutai^® in the United States, aiming for approval as early as 2027.

In December, we also entered into a strategic collaboration with Wenzhou Medical University and the People’s Government of Ouhai District, Wenzhou, to foster a synergistic ‘government–university–enterprise’ model, further strengthening our capabilities in regenerative medicine. Supported by strong partnerships with local governments and leading academic institutions, we are well positioned to build a world-class biomedical ecosystem and enhance our end-to-end innovation capabilities.”
Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life.

For further information, please contact: ir@uni-bioscience.com

Rare operatic genres, often referred to as endangered theatrical forms, are typically characterized by strong regional identities, limited reach, scarce inheritors, and relatively small scale. Shaped over centuries, they embody distinctive musical styles and performance forms of high artistic value and deep cultural resonance. As an integral part of intangible cultural heritage, they preserve local dialects, customs, and cultural ideals..Their protection, transmission, and revitalization are essential to strengthening the foundations of Chinese opera and advancing the creative transformation and innovative development of traditional Chinese culture.

This year’s showcase drew participation from over 100 troupes nationwide, with 36 outstanding works selected. Covering genres such as Yong Opera, Qian Opera, Qi Opera, Dunqiang, and Yong Opera, the showcase highlighted recent progress in safeguarding and revitalizing China’s rare operatic traditions.

Hashtag: #BinzhouInformationOffice

The issuer is solely responsible for the content of this announcement.